Eli Lilly and Company (0Q1G.L)
| Previous close | 244.96 |
| Open | 0.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 4,996 |
| Market cap | 491.119B |
| Beta (5Y monthly) | 0.41 |
| PE ratio (TTM) | 0.83 |
| EPS (TTM) | 6.52 |
| Earnings date | 08 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Yahoo Finance Video
June PCE inflation print, auto earnings: Morning Brief
The Federal Reserve's preferred inflation gauge, the Personal Consumption Expenditures (PCE) index, showed prices rising at its slowest rate in over three years while core PCE data came largely in-line with expectations. Seana Smith and Jared Blikre help investors start the day off right, highlighting the biggest market stories this morning as the three major averages (^DJI, ^IXIC, ^GSPC) digest the June PCE print. Bank of America Securities head of US economics Michael Gapen joins the program to shine a light on how the Fed may be looking at the June PCE data, alongside other recent inflation prints, in terms of its interest rate cut strategy. Bernstein senior analyst Daniel Roeska also sits down with The Morning Brief team to cover the auto industry's earnings performance this week, including Tesla (TSLA) and Stellantis (STLA). Other top trending tickers on the Yahoo Finance platform include the 3M Company (MMM), Deckers Outdoor (DECK), DexCom (DXCM), Norfolk Southern (NSC), and Coursera (COUR). This post was written by Luke Carberry Mogan.
- Yahoo Finance Video
Eli Lilly loses $120B in value over Viking's GLP-1 progress
Pharmaceutical giant Eli Lilly (LLY) lost approximately $120 billion in market value this week following an announcement from competitor Viking Therapeutics (VKTX). The biotech company revealed promising progress toward developing its own weight-loss drug, potentially challenging Eli Lilly's dominance in this market. Yahoo Finance senior health reporter Anjalee Khemlani breaks down the details. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Angel Smith
Investor's Business DailyIs Eli Lilly Stock A Sell On A Second Stumble In Obesity Treatment?
Is Eli Lilly stock a sell after new rivals emerged from the woodwork with promising test results and plans for oral obesity drugs?
